Early FDG PET/CT Can ID Metabolic Changes in Advanced Melanoma
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 29, 2024 -- For patients with advanced melanoma, early 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging can identify metabolic changes that may predict response to pembrolizumab, according to a study published online Jan. 24 in Clinical Cancer Research.
Thomas M. Anderson, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues prospectively enrolled 19 patients with advanced melanoma scheduled to receive pembrolizumab. At baseline and approximately one week after starting treatment, FDG PET/CT imaging was performed. These scans were assessed for changes in the maximum standardized uptake value (SUVmax); receiver operating curve analysis was used to identify thresholds, with metabolic flare (MF) defined as >70 percent increase in tumor SUVmax and metabolic response (MR) defined as >30 percent decrease in tumor SUVmax.
The researchers found that six of 11 responders and zero of eight nonresponders had an MF or MR, with an objective response rate of 100 and 38 percent in the MF-MR group and the stable metabolism (SM) groups, respectively. There was an association seen for MF or MR with T-cell reinvigoration in the peripheral blood and immune infiltration in the tumor. Overall survival at three years was 83 and 62 percent in the MF-MR and SM groups, respectively. The median progression-free survival was >38 and 2.8 months in the MF-MR and SM groups, respectively.
"An MF or MR was predictive of response, and strongly correlated with progression-free survival, suggesting that response assessment by early FDG PET/CT is robust," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
PECARN Prediction Rules for CT Imaging Show High Accuracy
FRIDAY, April 26, 2024 -- The Pediatric Emergency Care Applied Research Network (PECARN) intra-abdominal injury and traumatic brain injury rules show a high degree of accuracy in...
Gains in Heart Failure Mortality Have Been Erased
FRIDAY, April 26, 2024 -- Declines in heart failure-related mortality from 1999 to 2012 were entirely reversed from 2012 to 2021, according to a research letter published online...
AI Shows Good Clinical Knowledge, Reasoning for Eye Issues
FRIDAY, April 26, 2024 -- Large language models (LLMs) are approaching expert-level knowledge and reasoning skills in ophthalmology, according to a study published online April 17...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.